Condition

Pancreatic Adenocarcinoma clinical trials and research

• 56Clinical trials
• 25NIH research projects
• 26Countries

Newest Pancreatic Adenocarcinoma clinical trials

All recruiting trials (56)

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• Lorigerlimab in pancreatic cancer with BRCA/RAD51 gene mutations

  This phase 2 study tests Lorigerlimab in adults with metastatic pancreatic cancer who have BRCA1/2, PALB2, RAD51C, or RAD51D germline mutations.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07565155

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Removal of the pancreas and visible abdominal tumors plus heated chemotherapy in the belly for pancreatic cancer that has spread to the peritoneum.

  This trial will test whether removing the pancreas and visible abdominal tumors followed by heated intraperitoneal chemotherapy is safe and feasible for adults with pancreatic ductal adenocarcinoma who have limited peritoneal spread and have responded to at least six months of systemic chemotherapy.

  Recruiting Unidade Local de Saúde São João, Oporto · Shanghai, shangaiShanghai Municipality and 2 other locations · NCT07493421

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• ASP546C for adults with gastric/GEJ, pancreatic, and select other solid tumors

  This trial will test the experimental drug ASP546C given every three weeks to find the best dose and check safety in adults with gastric/GEJ cancer, pancreatic cancer, or certain other solid tumors.

  Recruiting at 21 sites Phase 1/2 Astellas Pharma Inc · Birmingham, Alabama and 20 other locations · NCT07488676

• 68Ga‑FAPI‑46 PET/CT to improve initial staging for pancreatic and bile duct cancer

  This will try 68Ga‑FAPI‑46 PET/CT scans in people newly diagnosed with pancreatic or bile duct cancer to see if they find hidden spread that CT or MRI miss.

  Recruiting Phase 2 University Hospital, Bordeaux · Pessac · NCT07478523

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Combining SBRT with defactinib and avutometinib for advanced pancreatic cancer

  This Phase 2 trial tests whether adding the targeted drugs defactinib and avutometinib to adaptive SBRT helps people with locally advanced or borderline resectable pancreatic cancer stay progression-free longer than SBRT alone.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07126158

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Analyzing bacterial overgrowth in pancreatic cancer patients

  This study is testing how common bacterial overgrowth is in pancreatic cancer patients who are losing weight and seeing if it relates to their surgery status.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT06988150

• 9‑ING‑41 and retifanlimab with modified FOLFIRINOX for advanced pancreatic cancer

  This tests whether adding the GSK‑3β inhibitor 9‑ING‑41 and the PD‑1 antibody retifanlimab to modified FOLFIRINOX helps people with advanced pancreatic cancer who have not had prior systemic therapy for their advanced disease.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT06896188

• Sotorasib plus first-line chemotherapy for KRAS p.G12C advanced pancreatic cancer

  This will test whether adding sotorasib to standard first-line chemotherapy helps people with advanced pancreatic cancer who have a KRAS p.G12C mutation.

  Recruiting at 16 sites Phase 1 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Avignon, France and 25 other locations · NCT06892054

• Examining the link between pancreatic steatosis and pancreatic cysts and cancer

  This study is trying to see if having fat in the pancreas is more common in people with pancreatic cysts that could turn into cancer and those with pancreatic cancer.

  Recruiting Carol Davila University of Medicine and Pharmacy · Bucharest, Sector 1 · NCT06867172

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination of medications for people with advanced pancreatic cancer to see if it helps them live longer and feel better.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Chaoyang District · NCT06789679

• Treatment for adult patients with solid tumors that have a specific p53 mutation

  This study is testing a new treatment for adults with advanced solid tumors that have a specific p53 mutation to see if it is safe and effective.

  Recruiting at 21 sites Phase 1 Clasp Therapeutics, Inc. · Scottsdale, Arizona and 20 other locations · NCT06778863

• BA1302 for advanced solid tumors

  This trial will test whether BA1302 is safe and helps people with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, breast cancer, and melanoma, who have progressed after or cannot have standard treatments.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing · NCT06596915

• Creating a biobank for studying bilio-pancreatic diseases

  This study is creating a collection of biological samples and health information to see how genes and environment affect the risk of bilio-pancreatic diseases.

  Recruiting IRCCS San Raffaele · Milan · NCT06552078

• Treatment for advanced basal-like pancreatic cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with advanced basal-like pancreatic cancer feel better when standard treatments aren't working.

  Recruiting Phase 1/2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06483555

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer who haven't had treatment before to see if it helps manage their disease better.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06405490

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

• Namodenoson treatment for advanced pancreatic cancer

  This study is testing a new oral medication called namodenoson to see if it can help people with advanced pancreatic cancer feel better and improve their condition.

  Recruiting Phase 2 Can-Fite BioPharma · Petah Tikva · NCT06387342

• Dostarlimab treatment for advanced or metastatic cancers with specific genetic markers

  This study is testing if the immunotherapy dostarlimab can help people with certain advanced cancers that have specific genetic markers feel better compared to standard chemotherapy.

  Recruiting Phase 2 Unicancer · Angers and 21 other locations · NCT06333314

• Combining chemotherapy and radiotherapy for advanced pancreatic cancer with elevated CA19-9 levels

  This study is testing if combining chemotherapy and radiation can help people with advanced pancreatic cancer and high CA19-9 levels live longer without their cancer getting worse.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06250972

• Treatment of Taxane-resistant Cancers with Paclitaxel Polymeric Micelles

  This study is testing a new form of chemotherapy called Paclitaxel Polymeric Micelles to see if it can help people with advanced cancers that didn't respond to standard Taxane treatments.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06199895

• Combining mFOLFIRINOX and radiotherapy for advanced pancreatic cancer with normal CA19-9 levels

  This study is testing if combining a specific chemotherapy and radiotherapy can help people with advanced pancreatic cancer who have normal CA19-9 levels live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06149689

• Cisplatin treatment for pancreatic cancer patients with specific genetic deficiencies

  This study is testing if a chemotherapy drug called cisplatin can help people with advanced pancreatic cancer who have specific genetic issues after their first treatment didn't work.

  Recruiting Phase 2/3 Fudan University · Shanghai · NCT06095141

• Using technology to improve care for pancreatic cancer patients

  This study is trying to see if sharing patient data among hospitals can help improve care and outcomes for people with pancreatic cancer.

  Recruiting UMC Utrecht · Utrecht · NCT06055010

• Intratumoral alpha-radiation seed implants for locally advanced pancreatic cancer

  This trial will try tiny alpha-radiation seed implants placed directly into tumors to see if they are safe and feasible for adults with locally advanced, unresectable pancreatic adenocarcinoma who have already had or cannot tolerate more chemotherapy.

  Recruiting Alpha Tau Medical LTD. · Verona · NCT06026943

• Dose-Painted Intensity Modulated Radiotherapy for Pancreatic Cancer

  This study is testing a new way of giving radiation therapy to people with certain types of pancreatic cancer to see how much they can safely handle and if it helps them better than standard treatment.

  Recruiting at 2 sites Phase 1/2 Cancer Trials Ireland · Dublin and 1 other locations · NCT06024824

• Assessing GTAEXS617 for advanced solid tumors

  This study is testing a new treatment called GTAEXS617 to see if it can help people with advanced solid tumors, like certain types of cancer, when other treatments haven't worked.

  Recruiting at 15 sites Phase 1/2 Exscientia AI Limited · Los Angeles, California and 14 other locations · NCT05985655

• Treatment with engineered T cells for advanced solid tumors with a specific mutation

  This study is testing a new T cell therapy for patients with advanced solid tumors that have a specific mutation to see if it can help fight their cancer.

  Recruiting at 16 sites Phase 1 AstraZeneca · Gilbert, Arizona and 19 other locations · NCT05877599

• Identifying markers to predict treatment response in pancreatic cancer patients

  This study is trying to find markers that can help doctors predict how well different treatments will work for people with pancreatic cancer.

  Recruiting at 7 sites GERCOR - Multidisciplinary Oncology Cooperative Group · Besançon and 14 other locations · NCT05776342

• Predicting survival in pancreatic cancer using the HELPP score

  This study is testing a new scoring system called the HELPP score to see if it can better predict survival and recurrence for patients with early-stage pancreatic cancer before they have surgery.

  Recruiting Medical University of Vienna · Vienna · NCT05752812

• Using alpha radiation emitters to treat advanced pancreatic cancer

  This study is testing a new type of radiation treatment for people with advanced pancreatic cancer to see if it can help shrink their tumors.

  Recruiting Alpha Tau Medical LTD. · Holon and 1 other locations · NCT05657743

• Combining NovoTTF-200T(P) with Gemcitabine and Nab-Paclitaxel for Treating Resectable Pancreatic Cancer

  This study is testing if a new treatment combining NovoTTF-200T(P) with two chemotherapy drugs can help people with resectable pancreatic cancer do better and have successful surgery.

  Recruiting Phase 2 Big Ten Cancer Research Consortium · Columbus, Ohio · NCT05624918

• Testing ASP2138 for stomach and pancreatic cancer treatment

  This study is testing a new drug called ASP2138 to see if it can help adults with stomach or pancreatic cancer by boosting their immune response when used alone or with standard treatments.

  Recruiting at 42 sites Phase 1 Astellas Pharma Inc · Orange, California and 45 other locations · NCT05365581

• Neoadjuvant chemotherapy for pancreatic cancer using different drug combinations

  This study is testing two different combinations of chemotherapy for people with pancreatic cancer to see which one works better before surgery.

  Recruiting Phase 2/3 Kochi University · Kochi · NCT05268692

• Testing MRTX1719 for solid tumors with MTAP deletion

  This study is testing a new drug called MRTX1719 to see if it can help people with advanced solid tumors that have a specific gene deletion.

  Recruiting at 22 sites Phase 1 Bristol-Myers Squibb · Phoenix, Arizona and 24 other locations · NCT05245500

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like lung and head and neck cancers, to see if it works better when combined with another treatment after other options have failed.

  Recruiting at 62 sites Phase 1 Seagen Inc. · Birmingham, Alabama and 61 other locations · NCT05208762

• Preoperative chemotherapy with radiation for borderline resectable pancreatic cancer

  This study is testing whether adding a specific type of radiation therapy to chemotherapy before surgery can help people with borderline resectable pancreatic cancer have better outcomes.

  Recruiting at 9 sites Phase 2 Erasme University Hospital · Antwerp and 9 other locations · NCT05083247

• Observing cancer recurrence using a blood test

  This study is testing a new blood test to see if it can help find out if cancer comes back in people who have been treated for early-stage solid tumors.

  Recruiting at 49 sites Guardant Health, Inc. · Birmingham, Alabama and 56 other locations · NCT05059444

• Combining Atezolizumab and Tivozanib for Treating Certain Cancer Types

  This study is testing a new combination of two cancer drugs, Atezolizumab and Tivozanib, to see if they can help people with tough-to-treat cancers like bile duct, gallbladder, breast, and neuroendocrine tumors.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT05000294

• Chemotherapy combined with anakinra for pancreatic adenocarcinoma

  This will try adding anakinra to pre- and post-operative chemotherapy in adults with resectable or locally advanced pancreatic adenocarcinoma to see if outcomes improve.

  Recruiting Phase 2 Baylor Research Institute · Dallas, Texas · NCT04926467

• Testing BMS-986340 alone and with other treatments for advanced solid tumors

  This study is testing a new treatment called BMS-986340, both on its own and with other drugs, to see how safe it is for people with advanced solid tumors.

  Recruiting at 39 sites Phase 1/2 Bristol-Myers Squibb · Clovis, California and 46 other locations · NCT04895709

• Combining irinotecan with multiple chemotherapy agents for cancer treatment

  This study is testing a new combination of chemotherapy drugs, including irinotecan, to see if it can safely help people with advanced gastrointestinal cancers like pancreatic and gastroesophageal junction adenocarcinoma who haven't had success with other treatments.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT04361708

• Dendritic cell therapy combined with chemotherapy for pancreatic cancer

  This study is testing a new treatment that combines a special type of immune cell therapy with chemotherapy to see if it helps people with pancreatic cancer after surgery.

  Recruiting at 3 sites Phase 1 Diakonos Oncology Corporation · Houston, Texas and 2 other locations · NCT04157127

• Combining a special virus with immune cells to treat advanced HER2 positive cancers

  This study is testing a new treatment that combines a special virus and immune cells to see if it can help people with advanced HER2 positive cancers.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT03740256

• Using a special dye to improve surgery for pancreatic cancer

  This study is testing a special dye to see if it can help doctors see pancreatic cancer better during surgery and make sure they remove all of it safely.

  Recruiting Phase 1/2 Stanford University · Palo Alto, California · NCT03384238

• Combining immunotherapy with irreversible electroporation for advanced pancreatic cancer

  This study is testing if combining a special cancer treatment called irreversible electroporation with the immunotherapy drug Nivolumab can help people with advanced pancreatic cancer do better than with standard treatments.

  Recruiting Phase 2 University of Louisville · Louisville, Kentucky · NCT03080974

• Examining the link between physical activity and survival in advanced cancer patients

  This study is testing how physical activity affects survival and overall health in people with advanced cancer by using wearable devices to track their activity levels.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT01365169

• Collecting medical information and tissue samples from patients with pancreatic disorders

  This study is collecting medical information and samples from people with pancreatic cancer or other pancreatic disorders to help find better ways to detect and treat these diseases.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT00830557

NIH-funded research (25)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• PASSCODE: Coordinating and Sharing PDAC stromal research data

  A networked effort at NYU School of Medicine aims to study how the pancreatic cancer stroma shapes tumor growth and patient outcomes, by coordinating researchers, sharing data, and educating the field.

  NIH research New York University School of Medicine · New York, United States · NIH-11413859

• Oncostatin M Receptor in Pancreatic Cancer

  Aims to understand how a molecule called Oncostatin M and its receptor affect pancreatic cancer to find new ways to help patients.

  NIH research Portland VA Medical Center · Portland, United States · NIH-11402385

• Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer

  A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11397470

• Low-dose, motion-aware MRI to study pancreatic cancer

  A new MRI method using low-dose contrast and motion-resolved imaging is being explored to better characterize pancreatic cancer in patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11394353

• SOAT1 as a target in pancreatic cancer

  Researchers are studying a specific enzyme, SOAT1, to see if blocking it can slow down or stop pancreatic cancer progression in models that mimic human disease.

  NIH research Cold Spring Harbor Laboratory · Cold Spring Harbor, United States · NIH-11360158

• Turning inflammatory scar cells in the pancreas into helpers to improve treatment response

  This project will try to change inflammatory, scar-forming cells around pancreatic tumors so treatments and the immune system can work better for people with pancreatic ductal adenocarcinoma.

  NIH research Stanford University · Stanford, United States · NIH-11338560

• Blocking cancer's iron supply to help pancreatic cancer drugs work better

  This project tests whether stopping pancreatic cancer cells from using stored iron can help people with KRAS-mutant pancreatic ductal adenocarcinoma respond longer to new KRAS-targeting drugs.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11311368

• uPAR-targeting antibody-drug conjugate for pancreatic cancer

  A first-in-class antibody-drug conjugate that targets uPAR on pancreatic cancer cells and surrounding support cells is being developed as a potential new therapy for pancreatic cancer.

  NIH research Traverse Biotech Ii INC · New York, UNITED STATES · NIH-11309753

• Blood markers to detect early pancreatic cancer

  Checking whether specific blood markers can help find early pancreatic cancer or identify people at higher risk, especially those with pancreatic cysts or a family history.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11307149

• Why some pancreatic cancers survive radiation

  Researchers are looking at whether signals from certain tumor cells make other pancreatic cancer cells resistant to radiation, with the goal of helping people with pancreatic cancer.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11184214

• Low-dose, motion-corrected MRI to improve pancreatic cancer imaging

  Testing a low-dose contrast MRI method that corrects for breathing and heart motion to create clearer images for people with pancreatic cancer.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11181183

• Intensive pre-surgery treatment for borderline and locally advanced pancreatic cancer

  This gives strong combination chemotherapy followed by high-dose targeted radiation before surgery for people with borderline resectable or locally advanced pancreatic cancer to shrink tumors and make surgery possible.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11169814

• Investigating how iron metabolism affects treatment resistance in pancreatic cancer

  This study is looking at how some pancreatic cancer patients become resistant to new treatments and aims to find better ways to help them by understanding how iron in the body affects cancer cells, which could lead to more effective therapies.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11162898

• Improving MRI techniques for pancreatic cancer diagnosis

  This study is testing a new type of MRI that uses less radiation and can better see how pancreatic cancer is changing, making it safer and more accurate for patients like you.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11142157

• How the Oncostatin M receptor helps drive pancreatic cancer

  This project looks at whether blocking the Oncostatin M receptor can slow aggressive pancreatic ductal adenocarcinoma in people.

  NIH research Portland VA Medical Center · Portland, United States · NIH-11118675

• Investigating a new treatment approach for pancreatic cancer with specific genetic mutations

  This study is looking at a type of pancreatic cancer that has certain genetic changes, and it aims to understand how a protein called polymerase theta helps these cancer cells survive, so that new treatments can be developed to work better alongside current therapies for patients with specific genetic mutations.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11100866

• Using advanced technology to improve the diagnosis of pancreatic cancer

  This study is working on a new, gentle way to help find early signs of pancreatic cancer by looking at tiny particles in your blood, which could lead to quicker and more accurate diagnoses for patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11095725

• Understanding how tRNA affects pancreatic cancer outcomes

  This study is looking at how certain types of tRNA might affect the growth and treatment response of pancreatic cancer, with the goal of finding new ways to help patients get better care tailored to their specific cancer.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11001096

• Understanding how different cancer cell types in pancreatic cancer respond to radiation

  This study is looking at how different types of cancer cells in pancreatic cancer respond to radiation therapy, with the hope of finding better ways to help patients get more effective treatment.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-10918091

• Understanding the role of the tumor environment in pancreatic cancer

  This study is looking at how certain supportive cells in the environment around pancreatic cancer tumors affect the growth of the disease, with the hope that this research will lead to better treatments for patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10915479

• New treatment approach for difficult-to-surgically-remove pancreatic cancer

  This study is looking at a new way to treat patients with tough-to-reach pancreatic cancer by giving them chemotherapy and radiation before surgery to help shrink the tumors and make surgery more successful.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10908415

• Investigating how obesity contributes to pancreatic cancer and ways to prevent it

  This study is looking at how being overweight can lead to pancreatic cancer, and it’s for anyone interested in understanding this link better, as well as finding ways to prevent the disease using new treatments.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-10832001

• Investigating the role of Oncostatin M in pancreatic cancer

  This study is looking at how a molecule called Oncostatin M affects pancreatic cancer cells and their surroundings, with the goal of finding new ways to help patients with this tough-to-treat cancer live longer and have better treatment options.

  NIH research Portland VA Medical Center · Portland, United States · NIH-10807826

• Using bacteria to fight pancreatic cancer

  This study is exploring how a certain bacteria can help your immune system fight pancreatic cancer by injecting it directly into tumors, which might boost your body's ability to attack the cancer while protecting healthy cells.

  NIH research West Virginia University · Morgantown, United States · NIH-10662559

• Developing a new treatment for pancreatic cancer using targeted drug delivery

  This study is testing a new oral medication called ACXT-3102 that aims to specifically attack pancreatic cancer cells while being gentle on healthy cells, making treatment easier and more effective for patients.

  NIH research Accuronix Therapeutics, INC. · St. Louis, UNITED STATES · NIH-10435565

Related topics

Quick answers

How many Pancreatic Adenocarcinoma clinical trials are recruiting right now?

56, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (33 trials), China (11 trials), Italy (8 trials), Spain (8 trials), France (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 14, Phase 2: 13, Phase 1/2: 8, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →